Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Finalizes Phase III Plans For Aducanumab In Alzheimer’s

Executive Summary

Though performance of a middle 6 mg/kg dose cohort just disappointed investors in the Phase Ib PRIME trial, company is confident with using this regimen in two large Phase III studies.

Advertisement

Related Content

Alzheimer’s Drugs Take Baby Steps Toward Brighter Future
Jury Still Out On Beta Amyloid Target In Early Alzheimer’s

Topics

Advertisement
UsernamePublicRestriction

Register

PS057020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel